Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.58 |
| ▸ | ACLY | P53396 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119048 | 0.88 | GHSR (0.58) | GHSRACLYALDH1A1MAPT | |
| SCHEMBL2122153 | 0.88 | GHSR (0.58) | GHSRACLYALDH1A1MAPT | |
| SCHEMBL2119666 | 0.86 | GHSR (0.56) | GHSRACLYALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2119636 | 0.82 | GHSR (0.52) | GHSRACLYALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2121431 | 0.81 | POLB (0.54) | ALDH1A1TP53MAPTSMN1; SMN2POLB | |
| SCHEMBL2121413 | 0.80 | GHSR (0.50) | GHSRACLYALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2117478 | 0.80 | GHSR (0.50) | GHSRACLYALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2119981 | 0.79 | ALDH1A1 (0.60) | ALDH1A1TP53MAPTSMN1; SMN2POLB | |
| SCHEMBL2118436 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TP53MAPTSMN1; SMN2POLB | |
| SCHEMBL2118481 | 0.79 | GHSR (0.49) | GHSRACLYALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095024-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095024-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1AN, HIF1A, EGLN2 | GHSR 2166/4885ACLY 1360/4885ALDH1A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.